Smith & Nephew (LSE:SN.)'s shares have crept higher through the summer as investors weigh whether the medical-technology group's long-promised turnaround is finally translating into durable profit growth. The London-listed maker of hip and knee implants, sports-medicine kit and advanced wound-care products delivered a mixed set of second-quarter and first-half figures on 4 August, pairing genuinely improved margins with a downgrade to its Revenue expectations. The result captures the central tension in the Investment case: operational discipline is clearly bearing fruit, yet the Top Line remains stubbornly harder to move.

Margins improve, revenue guidance trimmed

First-half revenue reached $3,097m, up 4.6% on a reported basis and 2.3% underlying. The more telling numbers sat below the revenue line. Trading profit rose 8.1% to $566m, lifting the trading Margin 60 basis points to 18.3%, while adjusted Earnings Per Share climbed 11.0% to 47.7 cents. The Interim Dividend was raised 4% to 15.6 cents. Chief executive Deepak Nath's "12-Point Plan" has now delivered roughly $330m of cumulative savings, and the company reiterated its full-year targets of around 8% trading-profit growth, free Cash Flow of about $800m and a return on invested Capital above 10%.

The catch came on revenue, where management cut full-year underlying growth guidance from "around 6%" to "around 4%". The reduction reflects specific pressures rather than broad weakness. Advanced Wound Management was knocked by reimbursement changes affecting skin substitutes in the United States, leaving its margin down 10 basis points at 22.0%. Orthopaedics remained the soft spot, with weak US knee and hip implant demand, though a self-help drive still nudged its margin up 30 basis points to 13.0%. The standout was Sports Medicine & ENT, where margins expanded 160 basis points to 24.7%, underlining the value of the higher-growth Franchise that first attracted activist attention.

Activist pressure and the recovery question

That activist dimension has become impossible to ignore. Cevian Capital, the Swedish investor known for pushing European industrials to sharpen strategy and capital allocation, has continued building its holding, disclosing a stake above 14% in August 2026. Cevian's presence raises the stakes around every earnings update, sharpening scrutiny of whether Smith & Nephew (LSE:SN.) can close the performance gap with rivals such as Stryker and Zimmer Biomet, or whether more radical structural options, including a possible separation of its divisions, eventually come onto the table.

For all the noise, the recovery thesis rests on a straightforward proposition. Smith & Nephew operates in structurally growing end-markets, benefiting from ageing populations, rising surgical volumes and the shift toward less invasive procedures. The problem has never been the addressable market but execution: Supply reliability, US commercial delivery in orthopaedics, and the drag of a sprawling product portfolio. The margin trajectory suggests the internal fixes are working; the revenue downgrade suggests the external recovery in its weakest categories is slower and lumpier than hoped.

Risks remain material. US reimbursement policy is an unpredictable headwind, the orthopaedics market is fiercely competitive, and currency movements can swing reported figures for a Business that earns heavily in dollars while reporting to sterling-based investors. Tariff uncertainty affecting global medical-device supply chains adds a further variable. Set against that, the Balance Sheet is improving and cash generation is on track.

Investors will now watch several markers: whether orthopaedics stabilises into the second half, how quickly the wound-care reimbursement drag washes through, and, crucially, what Cevian does next. A firm that has spent years promising a turnaround is beginning to show the profitability to back the claim, but the revenue trim is a reminder that "recovery" and "resolved" are not yet the same thing.